Filtered By:
Cancer: Carcinoma
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 3372 results found since Jan 2013.
Expression of lncRNA MSC-AS1 in hepatocellular carcinoma cell lines and its effect on proliferation, apoptosis, and migration
CONCLUSION: MSC-AS1 was upregulated in HCC cells, and the downregulation of MSC-AS1 could inhibit cell proliferation, migration, and invasion and promote apoptosis of HCC cells.PMID:33625998 | PMC:PMC7928261 | DOI:10.5152/tjg.2020.19485
Source: The Turkish Journal of Gastroenterology - February 24, 2021 Category: Gastroenterology Authors: Xiaoni Kou Jiang Zhu Xinke Xie Mingxia Hao Yingren Zhao Source Type: research
Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro
Conclusions:
This study indicated that a FSHR-mediated delivery system could mediate the highly selective delivery of siRNA into ovarian cancer cells and that silencing gro-alpha expression could be a potential choice for ovarian cancer treatment.
Source: Journal of Ovarian Research - November 20, 2013 Category: Cancer & Oncology Authors: Shanshan HongXiaoyan ZhangJun ChenJiabing ZhouYufang ZhengCongjian Xu Source Type: research
FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein
Abstract
F-box/WD repeat-containing protein 7 (FBW7) is a member of the F-box protein family that regulates cell cycle progression and cell growth and differentiation. FBW7 also functions as a tumor suppressor. A cisplatin (CDDP)-based multidrug chemotherapy regimen is standard for nasopharyngeal carcinoma (NPC), but drug resistance is an increasing problem. Here, we evaluated the relationship between FBW7 and multidrug resistance-associated protein (MRP), and its correlation with drug resistance in NPC, and explored the mechanism underlying drug resistance to CDDP in this disease. We used cell viability assays, W...
Source: Tumor Biology - January 14, 2015 Category: Cancer & Oncology Source Type: research
Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma
Conclusions
The inhibition of DDR2 by RNA interference suppressed in vivo and in vitro growth of human HCC cells. Our results may support that the use of DDR2 as a novel target of HCC treatment through control of tumor apoptosis, migration, and invasion.
Source: Journal of Cancer Research and Clinical Oncology - April 4, 2015 Category: Cancer & Oncology Source Type: research
Silencing of CXCR4 and CXCR7 expression by RNA interference suppresses human endometrial carcinoma growth in vivo.
Authors: Huang Y, Ye Y, Long P, Zhao S, Zhang L, A Y
Abstract
In this paper, the effect of silencing the expression of CXCR4 and CXCR7 by RNAi on the growth of endometrial carcinoma (EC), in vivo, was evaluated. To establish endometrial carcinoma model, thirty nude mice were subcutaneously inoculated with 1 × 10(7) Ishikawa cells. All tumor-bearing mice were randomly assigned to five groups (six mice in each group) when the tumor xenografts reached 5-7 mm in diameter, and treated with CXCR4-siRNA (5 nmol), CXCR7-siRNA (5 nmol), CXCR4-siRNA (5 nmol) plus CXCR7-siRNA (5 nmol), negative-siRNA (5 nmol) and normal sali...
Source: American Journal of Translational Research - May 6, 2017 Category: Research Tags: Am J Transl Res Source Type: research
Expression of DCUN1D1 in laryngeal squamous cell carcinoma and its inhibiting effect on TU-177 cells after interfered by RNA.
This article is protected by copyright. All rights reserved.
PMID: 29164666 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Pharmacology and Physiology - November 22, 2017 Category: Drugs & Pharmacology Authors: Liu J, Shuang Y, Li C, Zhou X, Huang Y, Zhang L Tags: Clin Exp Pharmacol Physiol Source Type: research
Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo
Publication date: 25 August 2018 Source:International Journal of Pharmaceutics, Volume 547, Issues 1–2 Author(s): Qian-Yu Zhang, Pui Yan Ho, Mei-Juan Tu, Joseph L. Jilek, Qiu-Xia Chen, Su Zeng, Ai-Ming Yu Recently we have established a novel approach to produce bioengineered noncoding RNA agents (BERAs) in living cells that carry target RNAi molecules (e.g., siRNA and miRNA) and thus act as “prodrugs”. Using GFP-siRNA-loaded BERA (BERA/GFP-siRNA) as a model molecule, this study was to define the in vitro and in vivo knockdown efficiency of BERAs delivered by liposome-polyethylenimine nanocomplex (lipopolyplex or LPP...
Source: International Journal of Pharmaceutics - June 18, 2018 Category: Drugs & Pharmacology Source Type: research
